Benitec Biopharma Provides Positive Updates on the BB-301 Pilot Dosing Study in Large Animals

HAYWARD, Calif.: HAYWARD, Calif., Sept. 8, 2021 /PRNewswire/ -- Benitec Biopharma Inc. (NASDAQ: BNTC), a development-stage biotechnology company focused on the advancement of novel genetic medicines, today provided an update on the ongoing analyses of the large animal subjects treated with BB-301 in the Pilot Dosing Study. Interim data from...

Click to view original post